NKGen Biotech to Present on Troculeucel for Neurodegenerative Diseases at 4th Great Bay Cell and Gene Therapy Forum
SANTA ANA, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. OTC:NKGN (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced tha…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.